Cutaneous Squamous Cell Carcinoma Market Size, Share, Treatment Trends and Forecast 2035

Cutaneous Squamous Cell Carcinoma Market Size and Forecast 2035

The global cutaneous squamous cell carcinoma market is estimated at USD 2.00 billion in 2025 and is forecast to reach USD 4.01 billion by 2035, expanding at a CAGR of 7.2% during 2026–2035.

cSCC is the second most common form of skin cancer in the United States. The Skin Cancer Foundation estimates 1.8 million SCC cases are diagnosed annually in the U.S., although non-melanoma skin cancers are incompletely captured by conventional cancer-registration systems.

Globally, IARC recorded 1.14 million non-melanoma skin cancer cases in 2024 in its registry-based category, with Northern America accounting for 52.1% of recorded incidence, Europe 21.4%, Asia 10.9%, Latin America and the Caribbean 7.4%, Oceania 5.7% and Africa 2.5%. This IARC category is broader than cSCC alone and should not be interpreted as a direct cSCC incidence count.

The commercial market is changing faster than the underlying epidemiology. Most localized cSCCs remain surgically curable, but high-risk, recurrent and advanced patients are increasingly entering prolonged PD-1 treatment pathways. The October 2025 approval of adjuvant cemiplimab extended immunotherapy beyond unresectable or metastatic disease into patients at high risk of recurrence after surgery and radiation.

Cutaneous Squamous Cell Carcinoma Market Highlites

• 2025 Market Size: USD 2.00 Billion
• 2035 Forecast Market Size: USD 4.01 Billion
• CAGR, 2026–2035: 7.2%
• Largest Region: North America – 44.8% share
• Fastest-Growing Region: Asia-Pacific
• Leading Treatment: Surgery & Mohs Surgery – 43.8% share
• Fastest-Growing Treatment: Immunotherapy
• Leading Disease Setting by Revenue: Localized cSCC – 58.5%

Cutaneous Squamous Cell Carcinoma Market Definition

Cutaneous squamous cell carcinoma is a malignant tumor arising from keratinizing squamous cells in the epidermis.

It should be distinguished from squamous cell carcinomas arising from mucosal surfaces such as the oral cavity, oropharynx, larynx, lung, cervix or esophagus. The term cutaneous specifically identifies squamous carcinoma originating in the skin.

The market includes diagnostic assessment and treatment of invasive cSCC, including surgical excision, Mohs micrographic surgery, radiation therapy, PD-1 immunotherapy, selected systemic therapies and other clinically appropriate local interventions.

NCI lists surgical excision, Mohs surgery, radiation therapy, curettage and electrodesiccation, cryosurgery and selected other local approaches for localized disease, while immunotherapy is an established treatment for metastatic or locally advanced cSCC that cannot be managed through curative local therapy.

The core market excludes basal cell carcinoma, melanoma, Merkel cell carcinoma and mucosal squamous cell cancers.

White-Space Opportunity: Immunosuppressed and Transplant Patients

One of the most commercially important unmet needs in cSCC is the population most difficult to treat with modern immunotherapy: solid-organ transplant recipients and other chronically immunosuppressed patients.

Immunosuppression substantially increases both cSCC incidence and aggressive disease risk. An NCI clinical-trial planning group reported that solid-organ transplant recipients can experience a 65- to 250-fold increase in cSCC incidence compared with the general population.

The therapeutic problem is significant.

PD-1 inhibition has transformed advanced cSCC in immune-intact patients, but checkpoint blockade may stimulate immune responses against a transplanted organ. Historically, transplant recipients have therefore been excluded from many pivotal immunotherapy studies.

That gap is becoming an active drug-development market.

In July 2026, a new Phase II study, CONTRAC-2, was posted to evaluate cemiplimab in kidney-transplant recipients with advanced cSCC using standardized sirolimus and prednisone immunosuppression. Cetuximab can be introduced as salvage therapy in the protocol. The study is expected to begin enrollment after September 2026.

A second NCI-sponsored Phase II trial began in March 2026 comparing subcutaneous amivantamab plus hyaluronidase with cetuximab in immunocompromised patients with recurrent inoperable or metastatic cSCC.

Oncolytic immunotherapy provides a third strategy. Replimune's ARTACUS study is evaluating intratumoral RP1 in organ and hematopoietic-cell transplant recipients with advanced cutaneous malignancies, including cSCC.

This population could become a distinct commercial submarket because the optimal product must deliver antitumor activity without creating an unacceptable risk of graft rejection.

Cutaneous Squamous Cell Carcinoma Market Key Takeaways

• The global market is estimated at USD 2.00 billion in 2025 and is forecast to reach USD 4.01 billion by 2035.
• Surgery and Mohs surgery remain the largest treatment segment, accounting for an estimated 43.8% of market value in 2025, reflecting the extremely large localized-disease population. This positioning is consistent with AAD guidance describing surgery as the most effective treatment for cSCC.
• Immunotherapy already accounts for an estimated 26.7% of market revenue and is expected to gain the most share through 2035.
• The principal reason is indication expansion. Cemiplimab is now used not only in metastatic or locally advanced cSCC that cannot be treated curatively with surgery or radiation, but also as adjuvant treatment after surgery and radiation in adults at high risk of recurrence.
• North America is modeled at 44.8% of 2025 revenue, reflecting very high skin-cancer incidence, established Mohs surgery capacity and comparatively rapid uptake of branded immunotherapy.
• Asia-Pacific remains the fastest-growing commercial region, supported by aging populations, improving dermatologic oncology services and higher treatment access in Australia, Japan, China and selected metropolitan Asian markets.
• The market is also becoming less dependent on intravenous systemic immunotherapy. Regeneron is running a Phase III study comparing intralesional cemiplimab with surgery in early-stage cSCC, potentially creating an entirely new therapeutic category if the approach demonstrates adequate efficacy and safety.

Cutaneous Squamous Cell Carcinoma Market Trends

Adjuvant Cemiplimab Has Created a New Treatment Market

The most important recent market event was the expansion of cemiplimab into high-risk resected disease.

On October 8, 2025, the FDA approved Libtayo for adults with cSCC at high risk of recurrence after surgery and radiation.

The C-POST Phase III trial enrolled 415 patients. Cemiplimab reduced the risk of disease recurrence or death by 68% compared with placebo, with a disease-free-survival hazard ratio of 0.32.

The commercial implications are substantial.

Previously, systemic PD-1 treatment was concentrated mainly in patients whose locally advanced or metastatic disease could not be cured through local treatment.

The adjuvant indication moves branded immunotherapy into a much earlier population where the visible tumor has already been removed but pathological features indicate high recurrence risk.

This increases both the eligible population and average pharmaceutical expenditure per high-risk cSCC case.

European access has also expanded. EMA's current Libtayo information includes adjuvant treatment of cSCC, with the European product information updated in December 2025.

The Adjuvant PD-1 Market Is Not a Class-Wide Success

The cemiplimab result is particularly important because another PD-1 inhibitor did not achieve the same result in a similar setting.

Merck discontinued KEYNOTE-630 in August 2024 after an interim analysis showed that adjuvant pembrolizumab did not cross the predefined statistical boundary for recurrence-free survival after surgery and radiation in high-risk locally advanced cSCC.

The study was subsequently completed, with the ClinicalTrials.gov record updated in March 2026.

The divergent Phase III outcomes strengthen Libtayo's competitive position rather than supporting a simple assumption that every checkpoint inhibitor will succeed in adjuvant cSCC.

Immunotherapy Is Moving Into Early Localized Disease

The next disruption could occur before surgery.

A global Phase III study initiated in January 2025 is comparing intralesional cemiplimab with primary surgery in adults with early-stage cSCC.

The trial plans 369 participants and has an estimated primary completion in 2030.

Instead of administering checkpoint therapy systemically, the treatment is injected directly into the tumor.

If successful, this could create an option for patients where surgery is undesirable because of location, cosmetic outcome, morbidity, or patient preference.

It would also materially change the traditional market boundary between procedural dermatology and pharmaceutical oncology.

Mohs Surgery Remains Difficult to Displace

Despite rapid immunotherapy growth, surgery remains dominant because most cSCC is localized when treated.

AAD guidance states that surgical therapy remains the most effective treatment for cSCC, with nonsurgical options generally reserved for selected low-risk tumors or situations where surgery is contraindicated.

Mohs micrographic surgery is particularly valuable where maximal tissue preservation and comprehensive margin assessment are important.

This often includes tumors on the face, ears and other anatomically sensitive locations.

The future market is therefore unlikely to become “immunotherapy instead of surgery.” It is more likely to evolve into risk-adapted combinations of surgery, radiation and immunotherapy.

Advanced cSCC Is Becoming a High-Value Chronic Oncology Market

Cemiplimab and pembrolizumab established PD-1 blockade for advanced disease.

Current Libtayo labeling includes adults with metastatic or locally advanced cSCC who are not candidates for curative surgery or curative radiation.

Pembrolizumab is approved for recurrent or metastatic cSCC that is not curable by surgery or radiation and has also been approved for locally advanced disease.

Unlike one-time surgical treatment, systemic immunotherapy can continue for an extended period when tolerated and effective.

This increases revenue per advanced patient and shifts commercial value disproportionately toward a relatively small subgroup of the total cSCC population.

The Market Is Moving Beyond Intravenous PD-1 Therapy

New investigational approaches are attempting to avoid some of the limitations of conventional intravenous checkpoint therapy.

Intralesional cemiplimab targets the tumor locally.

RP1 uses a modified HSV-1 oncolytic virus delivered directly into accessible tumors and is being studied specifically in transplant recipients and other advanced skin cancers.

The NCI's 2026 immunocompromised-patient study is evaluating subcutaneous amivantamab against cetuximab.

These development programs point toward a more diverse cSCC market in which delivery route and immune status may become as important as tumor stage.

Libtayo Has Reached Blockbuster Commercial Scale Across Its Portfolio

Regeneron reported USD 1.45 billion in global Libtayo sales in 2025, including USD 945 million in the United States and USD 508 million outside the U.S.

Those revenues include all approved Libtayo indications rather than cSCC alone and should not be interpreted as cSCC sales.

Nevertheless, the scale demonstrates the commercial infrastructure already supporting cemiplimab as its cSCC indications broaden.

Cutaneous Squamous Cell Carcinoma Market Scope

Cutaneous Squamous Cell Carcinoma Market Disruption Analysis

The traditional cSCC market followed a relatively simple pathway.

A suspicious lesion was biopsied, most invasive tumors were removed surgically, and radiation or systemic therapy was reserved for comparatively uncommon complex cases.

That model is being disrupted at both ends of the disease spectrum.

At the high-risk end, cemiplimab has created a systemic adjuvant market after definitive surgery and radiation.

At the low-risk end, intralesional cemiplimab is being tested directly against surgery in early-stage disease.

If both concepts are commercially successful, immunotherapy could eventually participate in treatment from early localized lesions through postoperative high-risk disease and into unresectable or metastatic cSCC.

A second disruption concerns the immunosuppressed population.

Historically, the patients with some of the highest cSCC risk have simultaneously been among the most difficult to treat with checkpoint inhibitors because of concerns about graft rejection or underlying immune dysfunction.

CONTRAC-2, the NCI amivantamab-versus-cetuximab study and ARTACUS are beginning to build a dedicated evidence base for this group.

A third disruption concerns the boundary between dermatology and medical oncology.

As branded systemic and intralesional medicines enter earlier disease, cSCC management increasingly requires collaboration between dermatologists, Mohs surgeons, head-and-neck surgeons, radiation oncologists and medical oncologists.

Cutaneous Squamous Cell Carcinoma Market Dynamics

High Disease Volume Creates a Large Procedural Market

The sheer frequency of cSCC is its principal volume driver.

The Skin Cancer Foundation estimates 1.8 million SCC diagnoses per year in the United States.

Most are managed successfully when detected early, which generates sustained demand for biopsy, histopathology, excision and Mohs surgery rather than systemic oncology drugs.

This distinguishes cSCC from many cancer markets in which metastatic drug treatment represents the majority of commercial value.

Aging Populations Increase the Addressable Patient Base

cSCC risk increases with cumulative ultraviolet exposure and age.

Skin Cancer Foundation guidance identifies age above 50 as a major risk factor, reflecting the cumulative effect of long-term ultraviolet exposure.

Aging populations in North America, Europe, Japan, Australia and other high-income markets therefore support sustained treatment growth even without dramatic changes in individual risk.

Immunotherapy Is Increasing Revenue Per High-Risk Patient

Most localized lesions involve finite procedural treatment.

High-risk and advanced disease can involve substantially greater expenditure because patients may receive surgery, radiation and prolonged systemic immunotherapy.

The 2025 adjuvant Libtayo approval creates exactly this kind of expanded pathway. Eligible patients can now receive up to 48 weeks of treatment after surgery and radiation.

This is one of the strongest reasons the pharmaceutical component should grow faster than overall case volume.

Immunosuppression Creates Both Risk and Therapeutic Complexity

Organ-transplant recipients and other chronically immunosuppressed patients experience greater cSCC risk and can develop more aggressive disease.

The NCI planning framework reports a 65- to 250-fold incidence increase among solid-organ transplant recipients.

Yet these patients have traditionally been poorly represented in checkpoint-inhibitor trials because stimulating the immune system may threaten a transplanted organ.

The resulting treatment gap supports demand for EGFR-directed drugs, altered immunosuppression strategies, intratumoral treatments and carefully controlled checkpoint approaches.

Surgical Cure Limits Pharmaceutical Penetration

High cure rates for localized disease constrain systemic-drug market penetration.

NCI lists surgery and Mohs surgery as principal localized cSCC treatments, while AAD emphasizes that surgery remains the most effective approach for most tumors.

A pharmaceutical product therefore needs to demonstrate a meaningful advantage in recurrence risk, morbidity, cosmetic outcome or treatment convenience before it can displace established surgery.

Checkpoint Toxicity Remains Relevant

PD-1 inhibitors can cause immune-mediated adverse reactions involving multiple organ systems.

The current Libtayo prescribing information includes warnings for immune-mediated toxicities and infusion-related reactions.

These effects are particularly relevant when extending systemic treatment into patients who may already have undergone potentially curative surgery.

Cutaneous Squamous Cell Carcinoma Market Segment Analysis

Surgery and Mohs Surgery Lead with 43.8%

Surgery and Mohs micrographic surgery are estimated to account for 43.8% of global cSCC market revenue in 2025, equivalent to around USD 876 million.

Their leadership reflects the very large localized-disease population.

AAD continues to describe surgical treatment as the most effective management approach for cSCC.

NCI lists excision with margin assessment and Mohs micrographic surgery among the main localized treatment options.

Mohs is particularly relevant where tumors are high risk or located in areas where preserving healthy tissue is clinically or cosmetically important.

The segment will continue growing in absolute value, but its percentage share is expected to decline as immunotherapy expands.

Immunotherapy Accounts for 26.7%

Immunotherapy is estimated to represent 26.7% of the 2025 market, or about USD 534 million, and is the fastest-growing treatment segment.

The category is led by cemiplimab and pembrolizumab.

Cemiplimab has the broadest current cSCC positioning because its U.S. indication now spans advanced disease and adjuvant therapy for patients at high risk of recurrence after surgery and radiation.

Pembrolizumab remains an important option for advanced cSCC but its KEYNOTE-630 adjuvant program did not demonstrate the required efficacy for continued development.

The gap between the two adjuvant results should support differentiated market share rather than treating PD-1 inhibitors as interchangeable.

Radiation Therapy Represents 13.9%

Radiation therapy accounts for an estimated 13.9% of market value in 2025, USD 278 million.

It is used when surgery is unsuitable, as definitive treatment in selected patients, and as postoperative treatment in high-risk disease.

Radiation has gained additional commercial relevance because the approved adjuvant cemiplimab population is specifically defined after surgery and radiation, making radiation oncology part of the new immunotherapy pathway.

Systemic Targeted and Cytotoxic Treatment Accounts for 8.2%

Non-checkpoint systemic treatment contributes 8.2% of market revenue, around USD 164 million.

Cetuximab remains a relevant EGFR-directed option, particularly where immune checkpoint treatment is unsuitable.

The 2026 NCI trial comparing amivantamab with cetuximab in immunocompromised advanced cSCC illustrates renewed interest in EGFR-directed treatment for a population with limited immunotherapy options.

Conventional cytotoxic chemotherapy now has a smaller role in advanced disease because PD-1 therapy has produced a more effective modern systemic treatment framework.

Other Local Treatments Represent 7.4%

Other local approaches account for an estimated 7.4%, or USD 148 million.

These include curettage and electrodesiccation, cryosurgery and selected superficial/local treatments in clinically appropriate lesions.

NCI notes that curettage/electrodesiccation and cryosurgery can be used in localized squamous cell skin cancer, although patient and tumor selection are important.

Localized Disease Generates 58.5% of Market Revenue

Localized cSCC is estimated to account for 58.5% of total 2025 market value.

The segment dominates because of high case numbers even though spending per individual patient is relatively modest.

High-risk resected cSCC contributes 22.8% of market revenue.

This segment is becoming commercially much more important after the adjuvant cemiplimab approval because a patient who previously generated primarily surgical and radiation expenditure may now enter almost a year of systemic therapy.

Locally advanced disease accounts for 11.6%, while metastatic disease represents around 7.1% of market revenue.

These latter groups contain far fewer patients but generate high treatment expenditure because of systemic therapy, multidisciplinary care and longer treatment duration.

Hospitals and Cancer Centers Lead the End-User Market

Hospitals and comprehensive cancer centers are estimated to account for 44.5% of global cSCC market revenue in 2025.

Their leadership is driven by radiation treatment, advanced surgery, nodal disease management and intravenous immunotherapy.

Dermatology and specialty skin-cancer clinics account for 35.5% and remain particularly important for biopsy, localized excision, Mohs surgery and surveillance.

Ambulatory surgical centers represent 14.0%, while other settings contribute about 6.0%.

The rapid increase in systemic and adjuvant immunotherapy should gradually shift a larger proportion of market value toward hospital- and cancer-center-based care.

Cutaneous Squamous Cell Carcinoma Market Geographical Analysis

North America Leads with 44.8% Market Share

North America is estimated to account for 44.8% of global cSCC market revenue in 2025, equivalent to around USD 896 million.

The region combines high ultraviolet-associated disease prevalence with extensive dermatology, Mohs surgery and oncology infrastructure.

IARC's broader non-melanoma skin cancer dataset shows that Northern America accounted for 52.1% of globally recorded NMSC incidence in 2024, reinforcing the region's unusually large underlying skin-cancer burden.

The United States accounts for an estimated 39.4% of global cSCC market value, representing USD 788 million in 2025.

The U.S. is the principal commercial market for advanced immunotherapy. It was the first market to approve cemiplimab for high-risk adjuvant cSCC in October 2025 and is hosting multiple early-stage, transplant and immunocompromised cSCC trials.

The Skin Cancer Foundation estimates 1.8 million SCC diagnoses annually in the country, demonstrating the exceptional treatment volume underlying the market.

Canada contributes an estimated 3.4% of global market revenue, around USD 68 million, while Mexico accounts for 2.0%.

North America should retain global revenue leadership through 2035, although its share is expected to moderate as other regions expand specialist treatment access.

Europe Represents 26.1%

Europe is estimated to hold 26.1% of global cSCC market revenue in 2025, or around USD 522 million.

IARC recorded 243,221 non-melanoma skin cancers in Europe during 2024, representing 21.4% of its global NMSC total.

European treatment revenue exceeds that incidence share in the market model because high-income countries have broad dermatology access, extensive surgical treatment and increasing uptake of systemic therapy.

Germany is estimated to represent 5.0% of global market revenue, around USD 100 million, making it the largest modeled European country.

The United Kingdom accounts for 4.4%, around USD 88 million, while France represents 3.9%, or USD 78 million.

Italy contributes 2.7% and Spain around 2.2%.

EMA's current Libtayo authorization includes adjuvant treatment for cSCC, expanding the European addressable immunotherapy population.

In the UK, NICE has begun developing a technology appraisal for adjuvant cemiplimab after surgery and radiotherapy, with final guidance currently expected in 2027.

Asia-Pacific Is the Fastest-Growing Market

Asia-Pacific is estimated to account for 21.4% of global cSCC market revenue in 2025, equivalent to about USD 428 million.

The region is expected to record the fastest growth, with a modeled CAGR of 9.2% through 2035.

Its market structure is unusually diverse.

Australia has among the world's highest age-standardized non-melanoma skin cancer incidence rates. IARC's 2024 data place Australia at the highest end of recorded NMSC incidence for both men and women.

Australia is therefore modeled as one of the largest individual Asia-Pacific cSCC treatment markets, accounting for 4.3% of global revenue, or around USD 86 million in 2025.

China represents an estimated 4.8% of global market value, around USD 96 million.

China's absolute skin-cancer incidence rates remain below Australia and North America, but its large population, improving dermatology infrastructure and growing access to oncology biologics create long-term commercial expansion potential.

Japan represents 3.4% of global revenue, or USD 68 million, supported by an aging population and established specialty healthcare infrastructure.

India accounts for 2.2%, around USD 44 million. Its current market is comparatively small, but greater dermatologic access and a growing elderly population should support expansion.

Asia-Pacific is expected to increase its global market share as systemic therapy penetrates beyond Australia and Japan into larger Asian markets.

Latin America Accounts for 4.5%

Latin America represents an estimated 4.5% of global cSCC market revenue in 2025, USD 90 million.

IARC's broader NMSC dataset recorded 84,270 cases in Latin America and the Caribbean in 2024, or 7.4% of globally registered cases.

The gap between incidence share and commercial revenue reflects lower treatment expenditure per case and uneven access to expensive systemic therapy.

Brazil is the largest modeled country market, contributing 2.2% of global revenue, or around USD 44 million.

Private tertiary hospitals increasingly provide advanced oncology treatment, but localized surgery continues to account for a larger percentage of regional spending than high-cost PD-1 therapy.

Middle East & Africa Represent 3.2%

Middle East & Africa are estimated to contribute 3.2% of global cSCC revenue in 2025, around USD 64 million.

The UAE and Saudi Arabia provide the largest premium-treatment opportunities in the Gulf because of investment in specialist healthcare and oncology.

South Africa remains one of the principal dermatology and oncology markets in Sub-Saharan Africa.

Skin-cancer epidemiology differs materially by skin type and geography. cSCC can occur in all populations, while disease in darker skin may also arise in chronically inflamed or scarred areas rather than following the same sun-exposure pattern seen in fair-skinned populations.

Access to Mohs surgery and checkpoint immunotherapy remains uneven across the region, limiting current commercial value despite unmet treatment need.

Cutaneous Squamous Cell Carcinoma Competitive Landscape

The cSCC competitive landscape is increasingly divided between procedural dermatology and systemic immuno-oncology.

Regeneron Pharmaceuticals

Regeneron currently holds the strongest branded pharmaceutical position through Libtayo (cemiplimab).

Its cSCC franchise now covers locally advanced and metastatic disease that cannot be managed with curative local treatment as well as high-risk adjuvant disease after surgery and radiation.

The October 2025 adjuvant approval gave cemiplimab a major competitive advantage following the positive C-POST trial.

Regeneron is also attempting to extend the franchise into early localized disease through the Phase III intralesional cemiplimab program.

Merck & Co.

Merck competes through Keytruda (pembrolizumab) in advanced cSCC.

Pembrolizumab is approved for recurrent or metastatic cSCC that cannot be cured through surgery or radiation and for locally advanced disease.

Its competitive position in adjuvant disease is weaker because KEYNOTE-630 was discontinued for futility after failing to meet the required recurrence-free-survival threshold.

Eli Lilly and EGFR-Directed Treatment

Cetuximab remains an important non-checkpoint treatment option in advanced squamous cancers and is used in selected cSCC settings where immunotherapy may be unsuitable.

Its strategic relevance may increase among immunocompromised and transplant patients.

The new NCI Phase II study comparing amivantamab plus hyaluronidase against cetuximab in immunocompromised recurrent or metastatic cSCC makes EGFR-directed therapy an active development area again.

Johnson & Johnson

Johnson & Johnson could become a new cSCC competitor through amivantamab, an EGFR/MET-directed antibody platform.

The ongoing NCI-sponsored Phase II trial is testing subcutaneous amivantamab against cetuximab specifically in immunocompromised advanced cSCC.

Success would create a particularly differentiated market position because the population has limited checkpoint-inhibitor options.

Replimune

Replimune represents the principal oncolytic-immunotherapy challenger through RP1.

The ARTACUS program is evaluating intratumoral RP1 in transplant recipients with advanced cutaneous malignancies, including cSCC.

The company previously reported encouraging response signals in transplant patients, although these remain clinical-development data rather than an approved cSCC indication.

Company Positioning

Established Immunotherapy Leader: Regeneron has the broadest current cSCC franchise because cemiplimab spans advanced and high-risk adjuvant disease.

Advanced-Disease Competitor: Merck retains an established position through pembrolizumab but lacks an approved high-risk adjuvant cSCC indication.

EGFR/Immunocompromised Opportunity: Cetuximab remains clinically relevant, while Johnson & Johnson's amivantamab program could create a next-generation targeted option.

Oncolytic Immunotherapy Challenger: Replimune is addressing one of the most underserved groups-transplant recipients-through intratumoral RP1.

Through 2035, the largest competitive opportunities are likely to occur in earlier-stage immunotherapy, transplant recipients, treatment after PD-1 failure and less invasive alternatives to surgery.

Recent Cutaneous Squamous Cell Carcinoma Market Developments

• July 20, 2026: A Phase II study of cemiplimab in kidney-transplant recipients with advanced cSCC, CONTRAC-2, was posted to ClinicalTrials.gov. The protocol uses standardized sirolimus and prednisone immunosuppression and allows cetuximab salvage treatment.
• July 13, 2026: The NCI Phase II trial comparing subcutaneous amivantamab with cetuximab in immunocompromised recurrent inoperable or metastatic cSCC was updated as recruiting.
• April 22, 2026: Regeneron's Phase III intralesional cemiplimab study in early-stage cSCC remained recruiting. The study directly compares intralesional immunotherapy with primary surgery and plans 369 participants.
• March 10, 2026: KEYNOTE-630 was updated as completed following its earlier discontinuation for futility in the high-risk adjuvant cSCC setting.
• January 30, 2026: Regeneron reported that Libtayo had obtained both U.S. and European approval as the first immunotherapy for high-risk adjuvant cSCC and recorded USD 1.45 billion in 2025 global Libtayo sales across all indications.
• October 8, 2025: FDA approved cemiplimab as adjuvant treatment for adults with cSCC at high risk of recurrence after surgery and radiation. C-POST demonstrated a 68% reduction in recurrence or death risk.
• May 31, 2025: Updated C-POST analyses continued to show substantial DFS benefit, including exploratory benefit across PD-L1 expression subgroups.
• January 2025: Regeneron announced the positive C-POST Phase III result, establishing the evidence base that subsequently supported the adjuvant FDA submission and approval.

Cutaneous Squamous Cell Carcinoma Treatment Selection and Procurement Priorities

Risk classification is the first major treatment decision.

Localized low-risk tumors can often be managed through surgery or other local approaches. High-risk characteristics-including tumor location, recurrence, size, depth, differentiation, perineural involvement and immune status-can substantially change the treatment pathway. AAD recommends formal cSCC risk stratification to guide management.

Margin control is particularly important when lesions occur in anatomically sensitive areas or have aggressive features. This supports the continuing role of Mohs micrographic surgery.

Radiation eligibility must be assessed for patients who cannot undergo surgery and for selected postoperative high-risk disease.

Adjuvant immunotherapy eligibility is now a new procurement consideration after the 2025 cemiplimab approval.

Not every surgically treated cSCC patient requires systemic treatment. Institutions must identify the high-risk population that matches the approved indication and supporting C-POST evidence.

Immune status requires separate consideration.

Solid-organ transplant recipients and other immunosuppressed patients may not be managed through the same checkpoint-inhibitor pathway as immune-intact patients because of graft and immune-related risks.

Infusion infrastructure matters as immunotherapy captures more cSCC revenue.

At the same time, intralesional and subcutaneous products under investigation could reduce dependence on conventional intravenous treatment if successful.

Finally, multidisciplinary coordination becomes increasingly important in advanced or high-risk cases, involving dermatology, Mohs surgery, head-and-neck surgery, radiation oncology, medical oncology, transplant medicine and pathology.

Strategic Opportunity Areas Through 2035

High-Risk Adjuvant cSCC

The C-POST approval has created a completely new commercial treatment segment.

The immediate opportunity lies in identifying high-risk postoperative patients and integrating almost one year of adjuvant cemiplimab into existing surgery-and-radiation pathways.

Immunosuppressed and Transplant Patients

This remains the clearest unmet need.

CONTRAC-2, amivantamab-versus-cetuximab and ARTACUS are testing three different approaches to a population that has historically been underrepresented in checkpoint studies.

Intralesional Immunotherapy

Direct tumor injection could change treatment economics for localized disease if it provides adequate control without the functional or cosmetic impact of surgery.

The current Phase III intralesional cemiplimab trial provides the clearest test of this model.

Post-PD-1 Treatment

As more patients receive cemiplimab or pembrolizumab, the number eventually progressing after checkpoint therapy will increase.

That creates a growing market for EGFR-directed treatments, combinations, oncolytic therapies and novel local approaches.

Better High-Risk Stratification

Only a minority of cSCC cases become clinically aggressive.

More accurate pathological, molecular and clinical risk tools could help identify patients requiring nodal assessment, radiation or adjuvant systemic therapy while avoiding overtreatment in the large low-risk population.

Asia-Pacific Expansion

Asia-Pacific remains commercially underpenetrated relative to its population and improving specialist-care infrastructure.

Australia already has one of the highest NMSC incidence rates globally, while China, Japan, India and South Korea provide substantial longer-term expansion potential.